Page 126 - 南京医科大学自然版

第46卷第7期
·1072 · 南 京 医 科 大 学 学 报 2026年7月

lung cancer patients based on the machine learning algo⁃ ［27］ROBERTS M E，RAHMAN N M，MASKELL N A，et al.
rithm［J］. Front Oncol，2024，14：1403392 British Thoracic Society guideline for pleural disease［J］.
［18］YANG S，PARK J W，MIN K，et al. Clinical practice Thorax，2023，78（11）：1143-1156
guidelines for oropharyngeal dysphagia［J］. Ann Rehabil ［28］CHEN J，XIE C，YANG Y，et al. Association between al⁃
Med，2023，47（Suppl 1）：S1-S26 bumin⁃to⁃globulin ratio and the risk of overall survival in
［19］WANG Y，NINABER D K，FAIZ A，et al. Acute cigarette advanced non⁃small cell lung cancer patients with anlo⁃
smoke exposure leads to higher viral infection in human tinib treatment：a retrospective cohort study［J］. BMC
bronchial epithelial cultures by altering interferon，glycol⁃ Pulm Med，2023，23（1）：275
ysis and GDF15⁃related pathways［J］. Respir Res，2023， ［29］WANG Y，LI S，HU X，et al. The prognostic value of se⁃
24（1）：207 rum albumin⁃globulin ratio in early⁃stage non⁃small cell
［20］WU W，TIAN L，ZHANG W，et al. Early IFN⁃β adminis⁃ lung cancer：a retrospective study［J］. Cancer Manag Res，
tration protects cigarette smoke exposed mice against le⁃ 2019，11：3545-3554
thal influenza virus infection without increasing lung in⁃ ［30］GUO Y，WEI L，PATEL S H，et al. Serum albumin：early
flammation［J］. Sci Rep，2022，12（1）：4080 prognostic marker of benefit for immune checkpoint inhib⁃
［21］RABY K L，MICHAELOUDES C，TONKIN J，et al. Mecha⁃ itor monotherapy but not chemoimmunotherapy［J］. Clin
nisms of airway epithelial injury and abnormal repair in Lung Cancer，2022，23（4）：345-355
asthma and COPD［J］. Front Immunol，2023，14：1201658 ［31］ZHANG X，ZHANG Y，ZHANG J，et al. Immunotherapy
［22］PESCH B，KENDZIA B，GUSTAVSSON P，et al. Cigarette of small cell lung cancer based on prognostic nutritional
smoking and lung cancer⁃⁃relative risk estimates for the index［J］. Front Immunol，2025，16：1560241
major histological types from a pooled analysis of case ⁃ ［32］MU Q，JING Y，DING Y，et al. Comprehensive prognostic
control studies［J］. Int J Cancer，2012，131（5）：1210- model for immunotherapy in small cell lung cancer：a
1219 multi⁃center study integrating clinical and blood biomark⁃
［23］ALP S，AKOVA M. Management of febrile neutropenia in ers［J］. Front Oncol，2025，15：1680624
the era of bacterial resistance［J］. Ther Adv Infect Dis， ［33］QIN K，GAY C M，BYERS L A，et al. The current and
2013，1（1）：37-43 emerging immunotherapy paradigm in small⁃cell lung can⁃
［24］WANG X，CHIANG A C. Big decisions on small cell lung cer［J］. Nature Cancer，2025，6（6）：954-966
cancer：a focus on clinical care updates and patient per⁃ ［34］LEE Y C，YEH H T，LU S W，et al. Diagnostic accuracy
spectives［J］. Am Soc Clin Oncol Educ Book，2024，44 of procalcitonin in adult non⁃neutropenic cancer patients
（3）：e432520 with suspected infection：a systematic review and meta ⁃
［25］KEIDAN N，AUJAYEB A. Small cell lung cancer and analysis［J］. BMC Infect Dis，2024，24（1）：278
pleural effusion：an analysis from a district general hospi⁃ ［35］POWELL M Z，MARA K C，BANSAL R，et al. Procalcito⁃
tal［J］. Pulm Ther，2023，9（3）：359-365 nin as a biomarker for predicting bacterial infection in chi⁃
［26］WESTLEY R，DE FONSEKA D，BEDAWI E O. Updates meric antigen receptor T⁃cell therapy recipients［J］. Can⁃
in the management of malignant pleural effusion：a clini⁃ cer Med，2023，12（8）：9228-9235
cal practice review［J］. J Thorac Dis，2025，17（8）：6283- （收稿：2026-04-01；修回：2026-06-01；录用：2026-06-02）
6295 （本文编辑：唐 震）